Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
EQS Newswire / 29/03/2023 / 11:05 UTC+8 Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China Suzhou, March 28, 2023 – Kintor Pharmaceutical Limited (“Kintor Pharma”,
More